Floatz logo

Indium In 111 Anti-Cd45 Monoclonal Antibody Bc8

Splenic Marginal Zone Lymphoma

Fred Hutchinson Cancer CenterradiopharmaceuticalPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

32 Active assets in the Splenic Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 3BB
Zanubrutinib
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Indium In 111 Anti-Cd45 Monoclonal Antibody Bc8 is also rated in:

myelodysplastic syndrome with excess blastsDormant
CC
Indicative ·
47 / 100
View asset →
myelodysplastic syndromeDormant
CC
Indicative ·
47 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →